Innovate Biopharmaceuticals has signed an agreement with Amarex Clinical Research to provide data management and biostatistics for its planned Phase 3 celiac disease trial. Under the agreement, Amarex will provide Innovate with electronic data capture solutions and associated services for data management and biostatistics. June Almenoff, M.D., Ph.D., F.A.C.P, chief medical officer and chief operating officer of Innovate said, “With their strong expertise in biostatistics and data management, I am pleased to be working with Amarex to support our Phase 3 trial. Our clinical team has been impressed with Amarex’s capabilities, and we look forward to a productive working relationship.” Kazem Kazempour, Ph.D., Amarex’s president and chief executive officer, said, “We are excited to support Innovate in the development of its novel therapeutic, which has the potential to help so many patients suffering from celiac disease. We look forward to working closely with Innovate’s experienced team to advance the clinical development of larazotide for this underserved population.”
Kazem Kazempour, Ph.D., Amarex’s president and chief executive officer, said, “We are excited to support Innovate in the development of its novel therapeutic, which has the potential to help so many patients suffering from celiac disease. We look forward to working closely with Innovate’s experienced team to advance the clinical development of larazotide for this underserved population.”
